share_log

AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense

SEC announcement ·  Apr 4 04:12
Summary by Futu AI
AbbVie Inc., a biopharmaceutical company, has released preliminary financial results for the first quarter of 2024, including an update on its earnings guidance. The company expects to report acquired IPR&D and milestones expense of $164 million on a pre-tax basis, which will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08. These results are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.97 to $11.17, reflecting the impact of the first quarter expenses. The first quarter adjusted diluted earnings per share guidance is set between $2.18 and $2.22, inclusive of the acquired IPR&D and milestones expense. The company's guidance for the remainder of the year excludes any potential acquired IPR&D and milestones expense due to the unpredictable nature of such transactions. AbbVie's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
AbbVie Inc., a biopharmaceutical company, has released preliminary financial results for the first quarter of 2024, including an update on its earnings guidance. The company expects to report acquired IPR&D and milestones expense of $164 million on a pre-tax basis, which will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08. These results are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.97 to $11.17, reflecting the impact of the first quarter expenses. The first quarter adjusted diluted earnings per share guidance is set between $2.18 and $2.22, inclusive of the acquired IPR&D and milestones expense. The company's guidance for the remainder of the year excludes any potential acquired IPR&D and milestones expense due to the unpredictable nature of such transactions. AbbVie's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.